Qiagen has entered into an agreement to transfer distribution rights for the Olerup sequence specific primer (SSP) product line and the related assets to Olerup International, a subsidiary
HEALTHPOINT has enrolled the first of a planned 235 subjects into a Phase-II dose response study, investigating an experimental, cell-based wound therapy, HP802-247. It is intended for the
Eli Lilly and Maryland-based MacroGenics have declared that the Protege trial has achieved its targeted patient enrollment. The Protege trial is a randomized, double-blind, multi-center, multi-national, 4-arm, controlled
Nuvo has entered into a license and development agreement with Covidien, to market and sell Pennsaid, and its follow-on product, Pennsaid Plus, in the US. Under the agreement,
AlphaRx and Gaia have provided latest updates on GAI-122, an investigational injectable nano-emulsion formulated with AlphaRx’s proprietary drug delivery technology. Gaia plans to initiate a clinical development program
CeNeRx has received the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909 is a
Pennsylvania-based Three Rivers Pharmaceuticals has announced positive results from phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures. Among participants who failed initial
Clarient has announced the launch of a new gene mutation test, that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The
The Healthcare & Science business of Thomson Reuters has announced that it is joining Research4Life to provide the developing world with access to critical scientific research. Special editions
Switzerland-based Lonza and US-based Elusys have entered into an agreement to produce Anthim. Anthim is a therapeutic monoclonal antibody in late stage of development for the treatment of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.